Evidence map›Paper›PMID 35881110›Full record

ArticleJournal of the European Academy of Dermatology and Venereology : JEADV2022

Genetic landscape of indolent and aggressive Kaposi sarcomas.

G G Malouf, X Lu, R Mouawad, J-P Spano, P Grange, F Yan, S Aractingi, X Su, N Dupin

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of the European Academy of Dermatology and Venereology : JEADV, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 4 countries.

G G MaloufDepartment of Medical Oncology, Institut de Cancérologie de Strasbourg, Strasbourg University, Strasbourg, France.
X LuDepartment of Cancer and Functional Genomics, Institute of Genetics and Molecular and Cellular Biology, CNRS/INSERM/UNISTRA, Illkirch, France.ORCID https://orcid.org/0000-0003-2417-6548
R MouawadDepartment of Medical Oncology, AP-HP, Hôpital Pitié-Salpêtrière, Sorbonne University, Paris, France.
J-P SpanoDepartment of Medical Oncology, AP-HP, Hôpital Pitié-Salpêtrière, Sorbonne University, Paris, France.
P GrangeDepartment of Dermatology, Cochin Hospital, Assistance Publique des Hôpitaux de Paris, Paris Cité University, Paris, France.
F YanState Key Laboratory of Natural Medicines, Research Center of Biostatistics and Computational Pharmacy, China Pharmaceutical University, Nanjing, China.
S AractingiDepartment of Dermatology, Cochin Hospital, Assistance Publique des Hôpitaux de Paris, Paris Cité University, Paris, France.
X SuDepartment of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
N DupinDepartment of Dermatology, Cochin Hospital, Assistance Publique des Hôpitaux de Paris, Paris Cité University, Paris, France.ORCID https://orcid.org/0000-0002-6237-4951
Délégation Paris 5 · FRCentre National de la Recherche Scientifique · FRSorbonne Université · FRChina Pharmaceutical University · CNThe University of Texas MD Anderson Cancer Center · US

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Fabien Delerue · 1985 to 2026
$290.8M
University of Texas M.D. Anderson Cancer SPORE-LeukemiaP50CA100632 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI SHPALL, ELIZABETH J · 2003 to 2023
$43.7M
Foundation AVECNCI NIH HHS P30 CA016672NCI NIH HHS P50 CA100632US National Institutes of Health
6 · The paper itself

Abstract

backgroundKaposi sarcoma (KS) is a rare skin tumour caused by herpesvirus 8 infection and characterized by either indolence or an aggressive course necessitating systemic therapies. The genetic basis of this difference remains unknown.

objectivesTo explore the tumour mutational burden in indolent and aggressive KS.

methodsWe performed whole-exome sequencing on a cohort of 21 KS patients. We compared genetic landscape including tumor mutational burden between the two forms of indolent and agressive KS.

resultsAggressive KS tumours had a significantly higher TMB and a larger cumulative number of deleterious mutations than indolent KS tumours. In addition, all aggressive tumours had at least three deleterious mutations, whereas most indolent tumours harboured only one or no predicted deleterious mutations. Deleterious mutations listed in the Cancer Gene Census were detected exclusively in patients with aggressive disease. An analysis of somatic copy-number alterations (SCNA) revealed a tendency towards higher number of alterations in aggressive KS.

conclusionsThese data suggest that SCNA alterations and an increase in mutational burden promote aggressive KS and that it might be more appropriate to consider indolent KS as an opportunistic skin disease rather than a cancer.

Indexed as

Acquired Immunodeficiency SyndromeHerpesvirus 8, HumanSarcoma, KaposiSkin NeoplasmsHumansMutation

Identifiers

PMID35881110
PMCPMC11803637
OpenAlexW4288036650

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.